国: ニュージーランド
言語: 英語
ソース: Medsafe (Medicines Safety Authority)
Metoprolol succinate 23.75mg;
AstraZeneca Limited
Metoprolol succinate 23.75 mg
23.75 mg
Modified release tablet
Active: Metoprolol succinate 23.75mg Excipient: Ethylcellulose Hydrated silica Hyprolose Hypromellose Liquid paraffin Macrogol 6000 Microcrystalline cellulose Sodium stearyl fumarate Titanium dioxide
Blister pack, PVC PVdC memory pack, 30 tablets
Prescription
Prescription
Ipca Laboratories Limited
· Hypertension. To reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · Angina pectoris. · Symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve New York Heart Association (NYHA) functional class and improve Quality of Life. · Cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · Maintenance treatment after myocardial infarction · Hyperthyroidism. · Functional heart disorder with palpitations. · Migraine prophylaxis. · Paediatric hypertension
Package - Contents - Shelf Life: Blister pack, PVC PVdC memory pack - 30 tablets - 36 months unopened stored at or below 30°C - Bottle, plastic, HDPE, tamperproof screw cap - - 36 months from date of manufacture stored at or below 30°C
1999-12-07
Betaloc® CR CMI 280320 Copyright 1(7) BETALOC ® CR METOPROLOL SUCCINATE, 23.75 MG, 47.5 MG, 95 MG, 190 MG CONTROLLED RELEASE TABLETS CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions people ask about BETALOC CR. It does not contain all the information that is known about BETALOC CR. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor will have weighed the risks of you taking BETALOC CR against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT BETALOC CR IS USED FOR BETALOC CR belongs to a group of medicines called beta-blockers. It works by affecting the body’s response to some nerve impulses, especially in the heart. As a result, it decreases the heart’s need for blood and oxygen and therefore reduces the amount of work the heart has to do. It also widens the blood vessels in the body, as well as helping the heart to beat more regularly. BETALOC CR is a controlled release tablet that releases its drug content in a time controlled manner. Controlled release tablets ensure a more even effect over 24 hours. BETALOC CR tablets are used for: lowering high blood pressure, also called hypertension, to reduce the risk of complications due to high blood pressure such as stroke, heart attack or early death. preventing angina (heart or chest pain brought on by stress or exercise in patients with coronary heart disease). treating or preventing heart attacks, or to reduce your risk of heart complications following a heart attack. treating heart failure (symptomatic mild to severe chronic heart failure in addition to other heart failure medicine), to help increase survival, reduce hospitalisation, improve symptoms, and quality of life. treating disturbances of heart rate in patients with heart disease, especially rapid heart beat. 完全なドキュメントを読む
Betaloc CR Data Sheet 120421 Copyright 1 NEW ZEALAND DATA SHEET 1. NAME OF MEDICINE B ETALOC ® CR 23.75 mg Modified release tablet B ETALOC ® CR 47.5 mg Modified release tablet B ETALOC ® CR 95 mg Modified release tablet B ETALOC ® CR 190 mg Modified release tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each modified release tablet contains metoprolol succinate 23.75 mg, 47.5 mg, 95 mg or 190 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Modified release tablets of metoprolol succinate, (will be referred to as controlled release tablets in the following text). CR tablets 23.75 mg – A controlled-release preparation in which the active substance metoprolol succinate, is embedded as coated beads in a disintegrating tablet. A white to off- white, oval, biconvex, film-coated tablet scored on both sides and engraved A/ on one side. Size: 5.5 x 10.5 mm. The tablet can be divided into equal doses. Average mass 0.17g. Each tablet contains 23.75 mg metoprolol succinate, bioequivalent to 25 mg metoprolol tartrate. CR tablets 47.5 mg - A controlled-release preparation in which the active substance metoprolol succinate is embedded as coated beads in a disintegrating tablet. A white to off- white, circular, biconvex, film-coated tablet with a score on one side and engraving A/m O on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. Diameter 9 mm. Average mass 0.22 g. Each tablet contains 47.5 mg metoprolol succinate, bioequivalent to 50 mg metoprolol tartrate. CR tablets 95 mg - A controlled-release preparation in which the active substance metoprolol succinate is embedded as coated beads in a disintegrating tablet. A white to off-white, circular, biconvex, film-coated tablet with a score on one side and engraving A/m S on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. Diameter 10 mm. Average mass 0.37 g. Each tablet contains 95 mg metoprolol 完全なドキュメントを読む